BlackRock Health Sciences Opportunities Fund Q3 2025 Commentary [Seeking Alpha]
Alnylam Pharmaceuticals, Inc. (ALNY)
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.alnylam.com/investor-overview
Company Research
Source: Seeking Alpha
An overweight position in Alnylam Pharmaceuticals was the top contributor at a security level. At a security level, an underweight position in AbbVie was the top detractor. The biotechnology company's stock rose following strong financial performance. Rachata Amnataree/iStock via Getty Images Commentary as of 09/30/25 The fund posted returns of 5.04% (Institutional shares)( SHSSX ) and 4.96% (Investor A shares, without sales charge)( SHSAX ) for the third quarter of 2025. The fund's performance was driven by security selection. At This article was written by Quick Insights Increasing exposure to pharmaceuticals and biotechnology enhanced returns, while reducing managed health care allocations limited upside in the rebounding managed care segment. Expectations of continued stock dispersion from innovation, technology, and policy, combined with below-average sector valuations and stable earnings, support the fund's constructive stance. Overweights in Alnylam (ALNY)
Show less
Read more
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNY alerts
High impacting Alnylam Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ALNY
News
- Alnylam Pharmaceuticals (NASDAQ:ALNY) was upgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "sell (d-)" rating to a "hold (c-)" rating.MarketBeat
- JPM26: 2025 a “breakout year” for rare disease biotechs [Yahoo! Finance]Yahoo! Finance
- Alnylam Pharmaceuticals (ALNY) Is Down 9.0% After Ambitious 2026 Guidance And 2030 Plan Reveal [Yahoo! Finance]Yahoo! Finance
- Adimab Reports Strong Partnering Year for 2025 [Yahoo! Finance]Yahoo! Finance
- Alnylam Pharmaceuticals Unveils “Alnylam 2030” as Amvuttra Drives Breakout Growth at JPMorgan Conf. [Yahoo! Finance]Yahoo! Finance
ALNY
Earnings
- 10/30/25 - Beat
ALNY
Sec Filings
- 1/14/26 - Form 4
- 1/14/26 - Form 4
- 1/14/26 - Form 4
- ALNY's page on the SEC website